NEW YORK, Sept. 16, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
PharmaPoint: Dry Eye Syndrome - India Drug Forecast and Market Analysis to 2022
GlobalData has released its new Country report, "PharmaPoint: Dry Eye Syndrome - India Drug Forecast and Market Analysis to 2022". Dry eye syndrome (DES), or keratoconjunctivitis sicca, is a multifactorial disease of the eye caused by dryness, decreased tear production, or increased tear film evaporation. DES, which is often referred to simply as dry eye, is the most prevalent form of ocular discomfort and irritation. The most common symptoms of DES are ocular irritation and discomfort, foreign body sensation, fatigue, and visual disturbances, which interfere with daily activities. In the elderly population, it is the most common reason for seeking eye care, and this is expected to increase exponentially with an aging demographic.
The DES market in India is projected to grow during the forecast period. During the forecast period, the primary market growth driver will be increased awareness of DES and overall improved access to medical care for India's enormous population.
Scope - Overview of the DES including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
Copyright©2012 PR Newswire.
All rights reserved